MediPal Holdings Corporation (7459)

Name: MediPal Holdings Corporation (7459) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-10-02

MediPal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. The company engages in the manufacture and supply of medical drugs, medical devices, medical supplies, clinical test reagents, and medical equipment and materials; non-life insurance agency business; outsourcing of medical office administration services; research and development of preventive medicine and cutting-edge medical technologies; and construction of a medical materials database.

Cifras clave

Capitalización bursátil: JPY 598 billion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 3.82T
Beneficio neto: JPY 42.5B
Margen bruto: 6.8%
Margen neto: 1.1%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	JPY 3.82T	JPY 3.67T	JPY 3.56T	JPY 3.36T
Beneficio bruto	JPY 261.0B	JPY 255.8B	JPY 246.7B	JPY 224.3B
Ingresos operativos (EBIT)	JPY 53.2B	JPY 55.6B	JPY 47.3B	JPY 49.0B
Ingresos netos	JPY 42.5B	JPY 40.3B	JPY 41.5B	JPY 38.8B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 7459. /companies/us/7459

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.